MKI67 and neuroendocrine neoplasm: Second-line therapy for grade 3 neuroendocrine tumors includes FOLFOX and FOLFIRI [49,50] in most cases with temozolomide-based regimens being preferentially used in grade 3 pancreatic neuroendocrine tumor or gastroenteropancreatic neuroendocrine tumor of other primary site with Ki-67 < 55% [48,51].